THERMO BIOPROCESS ONLINE EVENT SHORTS
Upstream Decisions Influence Downstream Challenges
In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), answer the question, “What should developers b...
Productivity Gains Upstream Apply Pressure Downstream
In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), reflect on the progress that’s been made in te...
Choosing The Right Metrics To Measure Process Performance
In this opening segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss what metrics matter the most to eval...
Simplifying Downstream Unit Operations To Increase Productivity
In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss the biggest opportunity to improve process y...
Using Better Tools And Better Data To Drive Process Productivity
In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” our panelists respond to an audience poll and answer audience questions about hollow fiber membranes and process modeling approaches. They agree ...
Continuous Manufacturing As A Powerful Productivity Lever
In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss the potential of perfusion and continuous ma...
Next-Generation Molecules Challenge Notions Of Yield And Performance
In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss how the process-related associated with next...
Understanding Fixed Variables And Working Within Their Constraints
Some things are intrinsic, unchanging realities of a process — molecular complexity, product developability, and facility fit, to name a few. In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,&rdqu...
Protecting Biopharma Manufacturing Supply Chains
In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers ...
Building Resilience In Biomanufacturing Operations
In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists share their thoughts on what it means to be resilient and how organizations can embody resilience in their biomanuf...
How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets?
In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also dis...
Bioprocessing Raw Material And Equipment Costs Are Slow To Recover Post-Pandemic
In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” our panel discusses how the still-high cost of materials and equipment is being factored into manufacturing decisions, as wel...
How Is U.S. Policy Reshaping Global Biomanufacturing Operations?
In this opening segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein speak candidly about how U.S. tariffs are affecting the glo...
Purification Strategies For Multispecifics
In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists Mark Fitchmun and Dr. Jian Ren debate the use of affinity resins compared to ion exchange and multimodal chroma...
Characterizing Product- And Process-Related Impurities In Multispecifics
In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists Mark Fitchmun and Dr. Jian Ren examine the types of common impurities manufacturers encounter in multispecific purificat...
Strategies For Viral Inactivation And Filtration In Multispecifics
In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists cover molecule sensitivity to low pH and the use of detergent-based viral inactivation, as well as evaluating t...
Addressing Manufacturability And Scalability Challenges In Multispecifics Purification
In this final segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists answer some remaining audience questions relating to viral inactivation, affinity resins, precipitation s...
Analytics Are The Eyes Of Process Development
In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” panelists Mark Fitchmun and Dr. Jian Ren emphasize the importance of good analytics for your purification strategy.
Involve CMC And Formulations Experts Early In Process Development
In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists talk about the cross-functional importance of formulations and CMC leads in process development.
Clinical Trial Strategy And ADC Dev Partnership
As the Bioprocess Online Live panel discussion Accelerating ADC Process Development wraps up, expert panelists Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) address audience questions on AI-d...
ADC Heterogeneity, Site-Specific Conjugation
This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipoph...
Linker And ADC Platform Manufacturing Technologies
In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, Dr. Léo Marx (Debiopharm) addresses advances in linker technology before he, Dr. Monika Lamba Saini (ADC Therapeutics) and Dr. Philipp Spycher (Araris Bi...
Challenges In ADC Process Development
Where does ADC process development fail? In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (...
AI In ADC Target Identification
How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clini...
ADCs & Speed To IND
In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC deve...
Outsourcing Considerations For Novel Protein Therapeutics
Panelists discuss special considerations for outsourcing the development and manufacturing of novel, complex protein therapeutics in this Bioprocess Online Live event.
Addressing Aggregation And Degradation In Complex Protein Therapeutics
In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss using a transient expression platform to make fast early product attribute decisions.
When To Conduct Analytical Assays In Novel Protein Therapeutic Development
Panelists in the Bioprocess Online Live event discuss the various points at which analytical assays are most critical during complex protein therapeutic development.
IND Prep Versus Clinical/Commercial Scale-Up In Novel Protein Therapeutics
In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists share detailed considerations for scale-up of complex protein therapeutics.
Addressing Post-Translational Modifications In Novel Protein Therapeutics
Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech, addresses an audience question on conjugation efficiencies in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics. From there, we move on to an audience-led ...